Literature DB >> 31404666

Increasing Liver Fat Is Associated With Incident Cardiovascular Risk Factors.

Katherine T Brunner1, Alison Pedley2, Joseph M Massaro3, Udo Hoffmann4, Emelia J Benjamin5, Michelle T Long6.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is associated with increased liver- and cardiovascular disease (CVD)-related morbidity and mortality. In cross-sectional analyses, NAFLD clusters with several cardiometabolic traits including obesity,1,2 hypertension,3 diabetes,1 and dyslipidemia.3 However, liver fat is dynamic and changes over time. Aside from limited prior studies evaluating diet or exercise interventions, little is known about the association between changes in liver fat and the incidence of CVD risk factors. Additionally, previous studies often have limited follow-up; evaluate only select populations, such as individuals with obesity4,5 or diabetes6-8; and may not account for changes in weight or body mass index (BMI). The aim of the present study was to examine, in a longitudinal cohort, the natural history of liver fat change and the association with the incidence of multiple CVD risk factors.
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 31404666      PMCID: PMC7007830          DOI: 10.1016/j.cgh.2019.08.003

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  8 in total

1.  The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Anna Mae Diehl; Elizabeth M Brunt; Kenneth Cusi; Michael Charlton; Arun J Sanyal
Journal:  Hepatology       Date:  2012-06       Impact factor: 17.425

Review 2.  Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.

Authors:  G Vernon; A Baranova; Z M Younossi
Journal:  Aliment Pharmacol Ther       Date:  2011-05-30       Impact factor: 8.171

3.  Dietary fat content modifies liver fat in overweight nondiabetic subjects.

Authors:  Jukka Westerbacka; Katriina Lammi; Anna-Maija Häkkinen; Aila Rissanen; Irma Salminen; Antti Aro; Hannele Yki-Järvinen
Journal:  J Clin Endocrinol Metab       Date:  2005-03-01       Impact factor: 5.958

4.  Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes.

Authors:  Mariana Lazo; Steven F Solga; Alena Horska; Susanne Bonekamp; Anna Mae Diehl; Frederick L Brancati; Lynne E Wagenknecht; F Xavier Pi-Sunyer; Steven E Kahn; Jeanne M Clark
Journal:  Diabetes Care       Date:  2010-07-27       Impact factor: 19.112

5.  Associates of change in liver fat content in the morbidly obese after laparoscopic gastric banding surgery.

Authors:  M L Phillips; S Boase; S Wahlroos; M Dugar; L Kow; J Stahl; J P Slavotinek; R Valentine; J Toouli; C H Thompson
Journal:  Diabetes Obes Metab       Date:  2007-10-17       Impact factor: 6.577

6.  Non-alcoholic fatty liver disease (NAFLD)--the hepatic component of metabolic syndrome.

Authors:  Deepa Uchil; D Pipalia; M Chawla; R Patel; Sonali Maniar; Archana Juneja
Journal:  J Assoc Physicians India       Date:  2009-03

7.  Low-Dose Levothyroxine Reduces Intrahepatic Lipid Content in Patients With Type 2 Diabetes Mellitus and NAFLD.

Authors:  Eveline Bruinstroop; Rinkoo Dalan; Yang Cao; Yong Mong Bee; Kurumbian Chandran; Li Wei Cho; Shui Boon Soh; Eng Kiong Teo; Sue-Anne Toh; Melvin Khee Shing Leow; Rohit A Sinha; Suresh Anand Sadananthan; Navin Michael; Heather M Stapleton; Christopher Leung; Peter W Angus; Sheila K Patel; Louise M Burrell; Su Chi Lim; Chee Fang Sum; S Sendhil Velan; Paul M Yen
Journal:  J Clin Endocrinol Metab       Date:  2018-07-01       Impact factor: 5.958

8.  High intensity intermittent exercise improves cardiac structure and function and reduces liver fat in patients with type 2 diabetes: a randomised controlled trial.

Authors:  Sophie Cassidy; Christian Thoma; Kate Hallsworth; Jehill Parikh; Kieren G Hollingsworth; Roy Taylor; Djordje G Jakovljevic; Michael I Trenell
Journal:  Diabetologia       Date:  2015-09-09       Impact factor: 10.122

  8 in total
  4 in total

1.  Distinct Cause of Death Profiles of Hospitalized Non-alcoholic Fatty Liver Disease: A 10 Years' Cross-Sectional Multicenter Study in China.

Authors:  Yansong Lin; Xiaorong Gong; Xin Li; Congxiang Shao; Tingfeng Wu; Minrui Li; Fuxi Li; Qianqian Ma; Junzhao Ye; Bihui Zhong
Journal:  Front Med (Lausanne)       Date:  2021-01-12

2.  The Repeatedly Elevated Fatty Liver Index Is Associated With Increased Mortality: A Population-Based Cohort Study.

Authors:  Chang-Hoon Lee; Kyung-Do Han; Da Hye Kim; Min-Sun Kwak
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-12       Impact factor: 5.555

3.  2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and Polychlorinated Biphenyl Coexposure Alters the Expression Profile of MicroRNAs in the Liver Associated with Atherosclerosis.

Authors:  Qiuli Shan; Fan Qu; Ningning Chen
Journal:  Biomed Res Int       Date:  2020-08-12       Impact factor: 3.411

4.  The association between hypertension and nonalcoholic fatty liver disease (NAFLD): literature evidence and systems biology analysis.

Authors:  Chongyang Ma; Kai Yan; Zisong Wang; Qiuyun Zhang; Lianyin Gao; Tian Xu; Jiayang Sai; Fafeng Cheng; Yuqiong Du
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.